|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The 'injury response':A concept linking nonspecific injury,acute rejection,and long-term transplant outcomes显示文摘 | Halloran PF Homik J Goes N | 1997 | Transplant Proc1997，29，： | 1 |
| 2 | Current standards of surgery for pancreatic cancer显示文摘 | Alexakis N Halloran C Raraty M | 2004 | Br J Sury2004，91，10： | 1 |
| 3 | Determination of mechanical injury and effects of bruising on the postharvest quality of cantaloupes显示文摘 | Halloran N Kasim M U Cagiran R | 1999 | Acta Horticulture1999，492，： | 1 |
| 4 | Sequencing reactions for the applied biasystems 373A Automated DNA sequencer显示文摘 | Halloran N Du Z Wilson RK | 1993 | Methods Mol Biol1993，23，： | 1 |
| 5 | Antimicrobial resistance and genetic diversity of Shigella sonnei isolates from western Ireland,an area of low incidence of infection显示文摘 | De Lappe N O'Halloran F Fanning S | 2003 | J Clin Microbiol2003，41，5： | 1 |
| 6 | Current standards of surgery for pancreatic cancer 显示文摘 | Alexakis N Halloran C Raraty M | 2004 | Br J Surg2004，91，11： | 1 |
| 7 | Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years显示文摘 | Gonwa T Johnson C Ahsan N Alfrey EJ Halloran P Stegall M Hardy M Metzger R Shield C 3rd Rocher L Scandling J Sorensen J Mulloy L Light J Corwin C Danovitch G Wachs M VanVeldhuisen P Leonhardt M Fitzsimmons WE | 2003 | Transplantation2003，75，12： | 1 |
| 8 | Current standard of urgery for pancreatic cancer显示文摘 | AIexakis N Halloran C Raraty hi | 2004 | Br J Surg2004，91，11： | 1 |
| 9 | Antimicrobial Resistance and Genetic Diversity of Shigella sonnei Isolates from Western Ireland,an Area of Low Incidence of Infection显示文摘 | DeLappe N O'Halloran F Fanning S | 2003 | J Clin Microbiol2003，41，5： | 1 |
| 10 | In vitro studies on the effect of particle size on macrophage responses to nanodiamond wear debris 显示文摘 | Thomas V Halloran BA Ambalavanan N | 2012 | Acta Biomater2012，8，5： | 1 |
| 11 | Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease显示文摘 | Pierce A Podlutskaya N Halloran JJ | 2013 | J Neurochem2013，124，6： | 1 |
| 12 | Sweet' s syndrome mimicking alkali burn: a clinical conundrum 显示文摘 | O' Halloran E Stewart N Vetrichevvel TP | 2013 | J Plast Reconstr Aesthet Surg2013，66，6： | 1 |
| 13 | Current standards o{ surgery for pancreatic cancer显示文摘 | ALEXAKIS N HALLORAN C RARATY M | 2004 | Br Surg2004，91，： | 1 |
| 14 | Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders显示文摘Immunosuppressive agents, such as thiopurines, methotrexate, and biologics, have revolutionized the treatment of inflammatory bowel disease(IBD). However, a number of case reports, case control studies and retrospective studies over the last decade have identified a concerning link between immunosuppression and lymphoproliferative disorders(LPDs), the oncological phenomenon whereby lymphocytes divide uncontrollably. These LPDs have been associated with Epstein-Barr virus(EBV) infection in which the virus provides the impetus for malignant transformation while immunosuppression hampers the immune system's ability to detect and clear these malignant cells. As such, the use of immunosuppressive agents may come at the cost of increased risk of developing LPD. While little is known about the LPD risk in IBD, more is known about immunosuppression in the post-transplantation setting and the development of EBV associated posttransplantation lymphoproliferative disorders(PTLD). In review of the PTLD literature, evidence is available to demonstrate that certain immune suppressants such as cyclosporine and T-lymphocyte modulators in particular are associated with an increased risk of PTLD development. As well, high doses of immunosuppressive agents and multiple immunosuppressive agent use are also linked to increased PTLD development. Here,we discuss these findings in context of IBD and what future studies can be taken to understand and reduce the risk of EBV-associated LPD development from immunosuppression use in IBD. | Grace Y Lam Brendan P Halloran Anthea C Peters Richard N Fedorak | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，4： | 1 |
| 15 | Current standards of surgery for pancreatic cancer 显示文摘 | Alexakis N Halloran C Raraty M | 2004 | Br Surg2004，91，11： | 1 |
| 16 | Current standards of surgery for pancreatic cancer显示文摘 | Alexakis N Halloran C Raraty M | 2004 | Br J Surg2004，91，11： | 1 |
| 17 | Increased major histocompatibility complex antigen expression in unilateral ischemia acute tubular necrosis in the mouse 显示文摘 | SHOSKES D A PARFREY N A HALLORAN P F | 1990 | Transplant1990，49，： | 1 |
| 18 | Current standards of surgery for pancreatic cancer显示文摘 | Alexakis N Halloran C Raraty M | 2004 | Br J Surg2004，91，11： | 1 |
| 19 | Altered DNA methylation profile in idiopathic pulmonary fibrosis 显示文摘 | Sanders YY Ambalavanan N Halloran B et at | 2012 | Am J Respir Crit Care Med2012，，186： | 1 |
| 20 | Curare standards of surgery for pancreatic cancer显示文摘 | Alexakis N Halloran C Raraty M | | 0，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员